聚金属氧酸盐在阿尔兹海默症治疗中的新进展  

Recent Advances on Polyoxometalates as Metallodrug Agents for Alzheimer’s Disease

作　　者：马蒙蒙 曲晓刚[1] MA Mengmeng;QU Xiaogang(State Key Laboratory of Rare Earth Resource Utilization,Laboratory of Chemical Biology,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences,Changchun 130022,China;College of Applied Chemistry and Engineering,University of Science and Technology of China,Hefei 230026,China)

机构地区：[1]中国科学院长春应用化学研究所稀土资源利用国家重点实验室,化学生物学实验室,长春130022 [2]中国科学技术大学应用化学与工程学院,合肥230026

出　　处：《高等学校化学学报》2020年第5期884-891,共8页Chemical Journal of Chinese Universities

基　　金：国家自然科学基金(批准号:21431007,21533008);中国科学院前沿科学项目(批准号:QYZDJ-SSW-SLH052)资助.

摘　　要：从聚金属氧酸盐(POMs)对β-淀粉样蛋白(Aβ)聚集的调控作用、水解及光动力治疗等方面介绍其在阿尔兹海默症(AD)治疗中的最新研究进展,为进一步研究POMs抗AD药物活性提供了参考.Alzheimer’s disease(AD)is a progressive neurodegenerative disorder characterized by cognitive dysfunction and memory loss.Although the exact pathogenesis of AD remains unclear,recent evidences have demonstrated that the accumulation and deposition ofβ-amyloid peptide(Aβ)is a key step in AD pathogenesis.Polyoxometalates(POMs)have the merits of adjustable structures,ease of preparation,and low cost,and thus have shown promising in AD treatment.Hence,recent advances on the POMs as a novel AD metallodrug agent are summarized.

关 键 词：阿尔兹海默症 聚金属氧酸盐 Β-淀粉样蛋白 

分 类 号：O614.6[理学—无机化学]